Drugs by condition
Drugs approved for kidney cancer (renal cell carcinoma)
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
24
Still marketed, NDA or BLA
Drug classes
8
Novel drugs
15
New molecular entities and new biologics
In development
29
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for kidney cancer (renal cell carcinoma).
- Omcazio (Cabozantinib Laurylsulfate) · Handa Oncol Sep 3, 2026
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
- Jobevne (Bevacizumab-Nwgd) · Biocon Biologics INC Apr 9, 2025
- Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024
- Vegzelma (Bevacizumab-Adcd) · Celltrion Sep 27, 2022
All approved drugs for kidney cancer (renal cell carcinoma), by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 24 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Vascular Endothelial Growth Factor Inhibitor (6)
Kinase Inhibitor (5)
- Lenvima Lenvatinib Mesylate · Eisai INC · 2015
- Inlyta Axitinib · Pf Prism Cv · 2012
- Afinitor Everolimus · Novartis · 2009
- Nexavar Sorafenib Tosylate · Bayer Hlthcare · 2005
- Afinitor Disperz Everolimus · Novartis Pharm · 2012
Endoglycosidase (2)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024
Programmed Death Receptor-1 Blocking Antibody (2)
Programmed Death Ligand-1 Blocker (1)
- Bavencio Avelumab · Emd Serono INC · 2017
CTLA-4-directed Blocking Antibody (1)
- Yervoy Ipilimumab · Bristol Myers Squibb · 2011
Lymphocyte Growth Factor (1)
- Proleukin Aldesleukin · Chiron · 1992
Class not listed in FDA's data (6)
Drugs in development for kidney cancer (renal cell carcinoma)
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- AbexinostatPCI-24781Phase 35 trials
Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- CasdatifanAB521Phase 33 trials
Arcus Biosciences, Inc. · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC)
- RO7247669Tobemstomig, RG6139Phase 26 trials
Roche (Genentech) · Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer
- EnvafolimabPhase 24 trials
3D Medicines (Sichuan) Co., Ltd. · Biliary Tract Neoplasms, Solid Tumor, Solid Tumors
- IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials
Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma
- PD-L1 t-haNKPhase 23 trials
ImmunityBio, Inc. · Pancreatic Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- ST-1898Phase 23 trials
Beijing Scitech-Mq Pharmaceuticals Limited · Advanced Renal Cell Carcinoma, Differentiated Thyroid Carcinoma, Unresectable or Metastatic Melanoma
- Carboplatin AUC-5Phase 22 trials
Inhibrx Biosciences, Inc · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
- GI-102Phase 22 trials
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
- REGN4336Phase 22 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- AB-2100Integrated Circuit T cellsPhase 21 trial
Arsenal Biosciences, Inc. · Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
- AZD6750Phase 21 trial
AstraZeneca · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)
More on kidney cancer (renal cell carcinoma): recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.